Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 601–700 of 1,000
Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Bhanot, S., & Leehey, D. J. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0612-7 · Cited by 15
Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New
Goldenberg, R., Berall, M. J., Chan, C. T., Cherney, D. Z. I., Lovshin, J. A., McFarlane, P. A., Senior, P. A., Verma, S., & Weinstein, J. J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.06.008 · Cited by 17
Emerging Therapy in Hypertension
Stewart, M. H., Lavie, C. J., & Ventura, H. O. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0923-1 · Cited by 15
The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
Gillard, P., Schnell, O., & Groop, P. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108462 · Cited by 14
Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
Ghosal, S., & Sinha, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1114894 · Cited by 15
“Both these attempts proved to be abortive (6, 7).”
BackgroundSchilders, J., Wu, H., Boomsma, F., van den Meiracker, A. H., & Danser, A. H. J. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6537-6 · Cited by 17
“, on kidney function, albumin excretion and Khandling, as evidenced by ONTARGET (ramipril + telmisartan) and ALTITUDE (aliskiren on top of an ACE inhibitor or an Ang II type 1 receptor blocker) [36, 37].”
BackgroundSequential RAAS Blockade: Is It Worth the Risk?
Persson, F., & Rossing, P. R. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.003 · Cited by 13
Self-citationA review of chemical therapies for treating diabetic hypertension
Sarafidis, P. A., Alexandrou, M. E., & Ruilope, L. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328054 · Cited by 16
“The subsequent Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) trial evaluated the effect of adding aliskiren 300 mg daily compared to placebo on top of standard therapy with ACEI or ARB on a primary composite cardio-renal end point [105].”
MethodFu, S., Wen, X., Han, F., Yin, L. W., & Xu, G. (2017) · Oncotarget · doi:10.18632/oncotarget.19382 · Cited by 13
“[6] The ASTRONAUT trial concluded aliskiren plus standard therapy did not reduce the rate of cardiovascular (CV) death or heart failure (HF) rehospitalization among hospitalizations for heart failure (HHF) patients.”
BackgroundInnovations in management of cardiac disease: drugs, treatment strategies and technology
Foëx, P. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex327 · Cited by 13
Chiang, M., Liang, C., Liu, C., Pan, B.-J., Chen, W., Yang, Y.-F., Lee, I., Tsai, J., Lee, C., & Chen, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00819 · Cited by 13
“Aliskiren does not influence the incidence of major cardiovascular events (Parving et al., 2012; Zhang et al., 2015).”
BackgroundPhysiology and Regulation of the Renin–Angiotensin–Aldosterone System
Carey, R. M., & Padia, S. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803247-3.00001-5 · Cited by 20
Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease
Provenzano, M., Maritati, F., Abenavoli, C., Bini, C., Corradetti, V., Manna, G. L., & Comai, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105719 · Cited by 18
Direct renin inhibition in chronic kidney disease
Persson, F., Rossing, P. R., & PARVING, H.-H. D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12072 · Cited by 13
Self-citationThe Dark Side of Blocking RAS in Diabetic Patients with Incipient or Manifested Nephropathy
Bolignano, D., Pisano, A., & Coppolino, G. (2015) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0035-1550017 · Cited by 14
Coca, A., López-Jaramillo, P. A., Thomopoulos, C., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001593 · Cited by 18
Blankestijn, P. J., Carrero, J. J., Clase, C. M., Deo, R., Herzog, C. A., Kasner, S. E., PASSMAN, R. S., Pecoits‐Filho, R., Reinecke, H., Shroff, G. R., et al. (2019) · Nephrology (Saint-Petersburg) · doi:10.24884/1561-6274-2019-23-2-18-40 · Cited by 14
Mancia, G., Schumacher, H., Böhm, M., Mann, J. F. E., Redón, J., Facchetti, R., Schmieder, R. E., Lonn, E., Teo, K. K., & Yusuf, S. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002567 · Cited by 14
Mallat, S. G. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-108 · Cited by 15
“an ARB increased risk of stroke in people with diabetes [100].”
BackgroundHu, S., Xie, H., Luo, R., Feng, P., Liu, Q., Han, M., Kong, Y., Zou, X., Wang, W., & Li, C. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01157 · Cited by 13
Combined angiotensin inhibition in diabetic nephropathy.
Fried, L. F., Emanuele, N., & Zhang, J. H. (2014) · PubMed · doi:10.1056/nejmc1315504 · Cited by 6
Capítulo 7 – Tratamento Medicamentoso
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160157 · Cited by 15
Wal, P., Tyagi, S., Pal, R. S., Yadav, A., & Jaiswal, R. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220426091238 · Cited by 16
Kintscher, U. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01998-0 · Cited by 12
“However, there was a slightly higher incidence of discontinuation due to hyperkalemia with finerenone, though lower than in trials with dual RAS-blockade [45 • , 46].”
Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases
Balakumar, P., & Jagadeesh, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_36 · Cited by 16
Preventing the development and progression of diabetic kidney disease: Where do we stand?
Zagkotsis, G., Markou, M. I., Paschou, E., Papanikolaou, P., & Sabanis, N. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.012 · Cited by 14
Idzerda, N. M. A., Persson, F., Pena, M. J., Brenner, B. M., Brunel, P., Chaturvedi, N., McMurray, J. J. V., PARVING, H.-H. D., de Zeeuw, D., & Heerspink, H. J. L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13465 · Cited by 12
“The study design and principal findings have been published previously.(8) In short, 8561 people with type 2 diabetes mellitus at high risk of cardiovascular and renal events were assigned to either aliskiren 300 mg/d or matched placebo in addition to antihypertensive therapy consisting of an individually titrated opt…”
Self-citationBjerre, H. L., Christensen, J., Buus, N. H., Simonsen, U., & Su, J. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-018-0149-8 · Cited by 14
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 13
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Nefrología · doi:10.1016/j.nefro.2021.10.003 · Cited by 16
Sukumaran, V., Gurusamy, N., Yalcin, H. C., & Venkatesh, S. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02651-x · Cited by 15
“Importantly, a combination of ARB or ACEi with the renin inhibitor Aliskiren did not improve cardiorenal endpoints in diabetic patients with renal impairment [133].”
BackgroundRole of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Alexandrou, M. E., Theodorakopoulou, M. P., & Sarafidis, P. A. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020019 · Cited by 12
“after publication of two major cardiovascular and renal outcome trials [9,10].”
MethodTreatment of diabetic kidney disease. A network meta-analysis
Büttner, F., Barbosa, C. V., Lang, H., Tian, Z., Melk, A., & Schmidt, B. M. W. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293183 · Cited by 14
“The premature stop of the large clinical trial ALTITUDE, where a DRI (Aliskiren) failed to show benefits in particular for hard renal endpoints, reflects unfavorable effects of DRI [26].”
Emerging drugs for chronic kidney disease
Stefoni, S., Cianciolo, G., Baraldi, O., Iorio, M., & Angelini, M. L. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.900044 · Cited by 12
“In December 2011, ALTITUDE was stopped prematurely on the recommendation of its Data Monitoring Committee due to increased incidence of hypotension, hyperkalemia, renal complications and nonfatal stroke in the aliskiren arm [52].”
MethodRoubille, F., Morena-Carrere, M., Leray‐Moragues, H., Canaud, B., Cristol, J., & Klouche, K. (2014) · Blood Purification · doi:10.1159/000361061 · Cited by 14
Viazzi, F. C., Leoncini, G., & Pontremoli, R. (2013) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-013-0027-y · Cited by 16
“The ALTITUDE study, which was conducted on 8,500 patients, had to be prematurely stopped due to what turned out to be a lack of benefit, possibly associated with a greater risk of complications [15].”
BackgroundMethodPharmacological Management of Diabetic Nephropathy
Papademetriou, V., Alataki, S., Stavropoulos, K., Papadopoulos, C. E., Bakogiannis, K., & Tsioufis, K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164749 · Cited by 14
Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice
Yang, S., Chen, Y., Duan, Y., Ma, C., Liu, L., Li, Q., Yang, J. A., Li, X., Zhao, B., Wang, Y., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109389 · Cited by 13
Imbalzano, E., Scarpelli, M., Mandraffino, G., Creazzo, M., Lizio, G., Trapani, G. D., Dattilo, G., Dalbeni, A., Tomasello, C., Sardo, M. A., et al. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320314530018 · Cited by 12
Rheinberger, M., Jung, B., Segiet, T., Nusser, J., Kreisel, G., Andreae, A., Manz, J., Haas, G., Banas, B., Stark, K. J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213157 · Cited by 13
Hui, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_6 · Cited by 13
Contrast-Induced Acute Kidney Injury
McCullough, P. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44942-7.00048-0 · Cited by 12
Trends of uncontrolled blood pressure in Spain
Catalá-López, F., Ridao-López, M., Sanfélix‐Gimeno, G., & Peiró, S. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835c6d19 · Cited by 12
“In summary, after updating our previous analyses [2], the current evidence continues to indicate that the control of BP in Spain is far from optimum and does not appear to have excessively improved in recent years.”
BackgroundMethodResultInfluentialProtein restriction: a revisited old strategy with new opportunities?
Locatelli, F., & Vecchio, L. D. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu218 · Cited by 11
“The IN F O C U S P r o t e i n r e s t r i c t i o n a n d C K D 1625Downloaded from https://academic.oup.com/ndt/article-abstract/29/9/1624/1867434 by guest on 28 July 2018 possible advantages of dual blocked have also received a significant stop following the publication of the Ongoing Telmisartan Alone and in Combi…”
ResultMiyasako, K., Maeoka, Y., & Masaki, T. (2024) · Biomedicines · doi:10.3390/biomedicines13010053 · Cited by 16
“However, combination therapy with multiple RAAS-is does not improve cardiovascular or renal outcomes, but rather it is associated with higher risks of hyperkalemia, hypotension, and acute kidney injury (AKI) [54,55].”
Bansal, N., Kathuria, D., Babu, A. M., Dhiman, S., Lakhanpal, S., Prasad, K. N., Kumar, R., Tyagi, Y., Kumar, B., Singh, M. P., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00720d · Cited by 14
Yuan, Y., Chen, C., Lin, Y., Luo, Y., Yang, Z., Guo, J., Liu, Q., Sun, L., & Fan, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1462965 · Cited by 14
Management of the Patient With Diabetes and Coronary Artery Disease: A Contemporary Review
Raymond, T. E., Raymond, R. E., & Lincoff, A. M. (2013) · Future Cardiology · doi:10.2217/fca.13.22 · Cited by 11
Chábová, V. Č., & Červenka, L. (2017) · Physiological Research · doi:10.33549/physiolres.933607 · Cited by 12
Tye, S. C., de Vries, S. T., Wanner, C., Denig, P., & Heerspink, H. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786706 · Cited by 12
“The designs and primary results of the individual trials have been previously published (Brenner et al., 2001; Lewis et al., 2001; Parving et al., 2012).”
BackgroundBlood Pressure Control in Patients with Diabetic Kidney Disease
Kim, Y., Kim, W. B., Kim, J.-K., Moon, J.-Y., Park, S., Park, C. W., Park, H. S., Song, S. H., Yoo, T., Lee, S.-Y., et al. (2022) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2022.20.2.39 · Cited by 13
Defining new surrogate markers for CKD progression
Schnaper, H. W., Furth, S. L., & Yao, L. P. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2995-0 · Cited by 12
Ohsawa, M., Tamura, K., Kanaoka, T., Wakui, H., Maeda, A., Dejima, T., Azushima, K., Uneda, K., Kobayashi, R., Tsurumi‐Ikeya, Y., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815361 · Cited by 15
“Although the addition of aliskiren to the ARB resulted in an additional reduction in proteinuria in CKD patients in the present study and those with diabetic nephropathy in the AVOID study [28], an increase in adverse events, such as hypotension and hyperkalemia, and no apparent benefits among patients randomized to a…”
BackgroundAliskiren directly improves endothelial progenitor cell function from Type II diabetic patients
Chang, T., Wu, T.-C., Huang, P., Chen, J.-S., Lin, L., Lin, S., & Chen, J. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12632 · Cited by 11
New antihypertensive medications and clinical implications
Wong, D., Tsai, P. N. W., Ip, K. Y., & Irwin, M. G. (2018) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2018.06.013 · Cited by 13
Recent therapeutic targets in diabetic nephropathy
Mohsen, M., Elberry, A. A., Rabea, A. M., Abdelrahim, M. E. A., & Hussein, R. R. S. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14650 · Cited by 12
Plasma Renin and Cardiovascular Risk: What Is the Evidence for an Association?
Volpe, M., & Unger, T. (2013) · Cardiology · doi:10.1159/000348365 · Cited by 11
Zhu, H., Chen, X., Cai, G., Zheng, Y., Liu, M., Liu, W., He, Y., Wang, Y., Li, W., Wu, H., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12347 · Cited by 11
“The ALTITUDE (Aliskiren Trial In Type 2 Diabetes Using Cardio-Renal Disease Endpoints) study found that the additional use of aliskiren in combination with standard ARB therapy could reduce proteinuria levels more effectively than the ARB alone, but that this combination therapy also led to an increased occurrence of…”
BackgroundSnyder, S., & John, J. S. (2014) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2014.08.010 · Cited by 14
Sánchez, M. A. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.08.003 · Cited by 16
Maranta, F., Spoladore, R., & Fragasso, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_169 · Cited by 12
Idzerda, N. M. A., Stefánsson, B. V., Pena, M. J., Sjöström, C. D., Wheeler, D. C., & Heerspink, H. J. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz064 · Cited by 14
“The design of ALTITUDE has been previously published [22].”
MethodRebuttal of the Pro View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD
Fried, L. F., & Lewis, J. B. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01610215 · Cited by 11
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Capric, V., Chandrakumar, H. P., Celenza-Salvatore, J., & Makaryus, A. N. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96415 · Cited by 11
A narrative review of new treatment options for chronic kidney disease in type 2 diabetes
Persson, F., Borg, R., & Rossing, P. R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4841 · Cited by 13
“Combining ACE inhibitors with ARB or renin inhibitors is not recommended as such a 'double blockade' increases the incidence of hyperkalaemia, hypotension and acute renal failure without improved efficacy (16-18).”
BackgroundSelf-citationRenin–angiotensin–aldosterone system and blood pressure regulation
Seravalle, G., & Grassi, G. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00002-9 · Cited by 16
miR-1187 induces podocyte injury and diabetic nephropathy through autophagy
Chen, B., & He, Q. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231172139 · Cited by 12
Does renal denervation require cardiovascular outcome-driven data?
Haider, S. A., Wagener, M., Iqbal, T., Shahzad, S., Sole, P. A. D., Leahy, N., Murphy, D., Sharif, R., Ullah, I., & Sharif, F. (2024) · Hypertension Research · doi:10.1038/s41440-024-01598-7 · Cited by 10
“For example, in the ALTITUDE trial, systolic and diastolic blood pressures were lower with aliskiren, a renin inhibitor, (between-group differences, 1.3 and 0.6 mm Hg, respectively) but there no difference in cardiovascular endpoints [48].”
BackgroundInfluentialMizuno, H., Hoshide, S., Fukutomi, M., & Kario, K. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12618 · Cited by 12
“However, a recent clinical trial showed that for patients with type 2 diabetes, the addition of aliskiren to standard therapy including RAAS inhibitors, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) did not reduce cardiovascular and renal events and in fact increased adverse e…”
BackgroundInfluentialAlhawassi, T. M., Krass, I., & Pont, L. (2015) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-015-0042-6 · Cited by 10
“The slow uptake of aliskiren for use among the elderly may be hindered by its limited efficacy and relatively poor safety profile.[51, 52]”
BackgroundVelde‐Keyzer, C. A. T., de Jong, M. A., van Breda, G. F., Vervloet, M. G., Laverman, G. D., Hemmelder, M. H., Janssen, W. M. T., Heerspink, H. J. L., Navis, G. J., & de Borst, M. H. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv033 · Cited by 11
“Rather, particularly in diabetic nephropathy patients, dual RAAS blockade was accompanied by an increased risk of acute kidney injury and hyperkalaemia [8–10].”
BackgroundEmerging drugs for managing kidney disease in patients with diabetes
Thomas, M. C. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.762356 · Cited by 11
“, no prospect of demonstrating the treatment benefit anticipated in the protocol) as well as safety concerns including an excess of renal dysfunction, hyperkalemia, hypotension and strokes [18].”
BackgroundExtreme Sodium Reductions for the Entire Population: Zealotry or Evidence Based?
Mente, A., O'Donnell, M. J., & Yusuf, S. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt148 · Cited by 11
Kröpelin, T. F., de Zeeuw, D., Remuzzi, G., Bilous, R., Parving, H., & Heerspink, H. J. L. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015101150 · Cited by 10
“The study designs and results of each trial are reported elsewhere and here briefly described .(3,6,11,12,16)”
BackgroundMethodSelf-citationConcepts in Diabetic Nephropathy: From Pathophysiology to Treatment
Kinaan, M., Yau, H., Martinez, S., & Kar, P. M. (2017) · Journal of Renal and Hepatic Disorders · doi:10.15586/jrenhep.2017.17 · Cited by 12
Mei, M., Zhou, Z., Zhang, Q., Chen, Y., Zhao, H., & Shen, B. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000513119 · Cited by 11
Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials
Norman, G. A. V. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.09.005 · Cited by 10
Recent Clinical Trials of Hypertension Management
Jennings, G. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.00863 · Cited by 11
Hypertension and Diabetic Nephropathy
Skov, J., Christiansen, J. S., & Poulsen, P. L. (2016) · Endocrine development · doi:10.1159/000439393 · Cited by 12
Novel approaches for treating hypertension
Freeman, A. J., Vinh, A., & Widdop, R. E. (2017) · F1000Research · doi:10.12688/f1000research.10117.1 · Cited by 12
Allen, C., & Donegan, K. L. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4219 · Cited by 10
“(1) NICE CG127 Hypertension guideline(12); (2) Parving et al.(6); (3) Makani et al.”
BackgroundHypertension Management in Chronic Kidney Disease and Diabetes
Thomas, G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.04.006 · Cited by 11
Chan, A. T. P., & Tang, S. C. W. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.285 · Cited by 11
“Despite a higher incidence of hyperkalemia in the finerenone arm of the FIDELIO-DKD study, the discontinuation rate was lower than in other clinical studies that combined a RAASi with a specific target and intervention for hyperkalemia during the study period [77,78].”
ResultNakamoto, H., Yu, X., Kim, S., Origasa, H., Zheng, H., Chen, J., Joo, K. W., Sritippayawan, S., Chen, Q., Chen, H., et al. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12840 · Cited by 10
Nefroprotección clásica: inhibidores del sistema renina angiotensina aldosterona
Egocheaga, M. I., Hernández, Y. D., & Otero, V. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102018 · Cited by 11
How to Choose the Right Treatment for Membranous Nephropathy
Peritore, L., Labbozzetta, V., Maressa, V., Casuscelli, C., Conti, G., Gembillo, G., & Santoro, D. (2023) · Medicina · doi:10.3390/medicina59111997 · Cited by 9
Obrador, G. T., Álvarez-Estévez, G., Bellorín-Font, E., Bonanno-Hidalgo, C., Clavero, R., Correa‐Rotter, R., Diná-Batlle, E., Morales, L., Orozco, R., Ortiz, F., et al. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000037 · Cited by 16
Yi, X., Yang, S., Yang, J., Chen, X., Zhang, A., Zeng, Q., Luo, W., Li, Q., & Hu, J. (2024) · Drugs · doi:10.1007/s40265-024-02092-7 · Cited by 9
“Randomized controlled trials (RCTs) showed that MRAs significantly reduced the risk of all-cause and cardiovascular mortality when compared to placebo [13, 14], while the efficacy of DRIs with regard to mortality seemed to be neutral [15] or even detrimental [16].”
Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trials
Wandel, S., Desai, A. S., Chen, C., McMurray, J. J. V., Packer, M., Solomon, S. D., Pfeffer, M. A., Felker, G. M., Zannad, F. M., Petrie, M. C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae753 · Cited by 9
Self-citationKobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 11
Capítulo 10 - Hipertensão na Criança e no Adolescente
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160160 · Cited by 10
Tye, S. C., de Vries, S. T., Mann, J. F. E., Schechter, M., Mosenzon, O., Denig, P., & Heerspink, H. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.786767 · Cited by 10
“The designs and primary outcomes for these trials have been previously published (Ruggenenti et al., 1997; Lewis et al., 2001; Parving et al., 2012).”
BackgroundFisiopatología renal y mecanismos farmacológicos de nefroprotección
Górriz, J. L., Górriz-Zambrano, C., & Pallarés‐Carratalá, V. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102021 · Cited by 14
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Hirota, K., Yamashita, A., Abe, E., Yamaji, T., Azushima, K., Tanaka, S., Taguchi, S., Tsukamoto, S., Wakui, H., & Tamura, K. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105478 · Cited by 9
“However, excessive inhibition of the RAS has been associated with adverse events including hypotension, hyperkalemia, and renal damage (12, 13).”
BackgroundExpanding options of supportive care in IgA nephropathy
Maixnerová, D., Hartinger, J. M., & Tesař, V. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad201 · Cited by 11
Morales, J., & Palmer, B. F. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2316572 · Cited by 9
“Implementing lifestyle adjustments, dietary modifications, and potassium binders in the appropriate clinical situation might help normalize potassium levels in patients using MRAs that are associated with a greater degree of hyperkalemia or even using nsMRA [51].”
BackgroundSaid, F., Arnott, C. G., Voors, A. A., Heerspink, H. J. L., & ter Maaten, J. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15592 · Cited by 10
Aldosterone synthase inhibition in chronic kidney disease
Theodorakopoulou, M. P., Iatridi, F., & Sarafidis, P. A. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001089 · Cited by 10
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.